MetLife director adds 10 shares via dividends

MetLife director Daniel S. Glaser received a small stock accrual via dividend reinvestment on deferred shares, modestly increasing his direct and GRAT-held positions.

Available on EDGAR 09/10/2026 - 04:02 PM EDT Accepted by SEC EDGAR 09/10/2026 - 04:01 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

METLIFE INC (MET) reported that director Daniel S. Glaser acquired 10 shares of common stock on September 8, 2026 through an imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors at a reference value of $95.50 per share. Following this grant, he holds 2,705 shares directly and an additional 198 shares indirectly through a GRAT.

Insider Trade Summary

Grant/Award: 10 shares

Grant/Award 1 txn

Insider Glaser Daniel S

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	10	$95.50	$955.00
Holding	Common Stock F2	--	--	--

Holdings After Transaction: Common Stock — 2,705 shares (Direct); Common Stock — 198 shares (Indirect, By GRAT)

Holdings Before and After: Common Stock, 2,695 to 2,705 shares (Direct)

Footnotes (2)

1. F1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.
2. F2. These shares are held in a GRAT.

Key Figures

Shares acquired: 10 shares Reference value per share: $95.50 per share Direct holdings after transaction: 2,705 shares +2 more

5 metrics

Shares acquired 10 shares Imputed dividend reinvestment on deferred shares on September 8, 2026

Reference value per share $95.50 per share Value used for the 10-share dividend reinvestment grant

Direct holdings after transaction 2,705 shares MetLife common stock held directly by Daniel S. Glaser after the grant

Indirect holdings via GRAT 198 shares MetLife common stock held indirectly by GRAT associated with Daniel S. Glaser

Total acquire-type transactions 1 transaction Grant, award, or other acquisition reported on this Form 4

Key Terms

MetLife Deferred Compensation Plan for Non-Management Directors, Deferred shares, GRAT, Imputed reinvestment of dividends

4 terms

MetLife Deferred Compensation Plan for Non-Management Directors financial

"Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors"

Deferred shares financial

"Deferred shares represent shares of MetLife, Inc. common stock that have become payable"

Deferred shares are a class of stock whose economic benefits or certain shareholder rights are delayed or paid later than ordinary shares—for example, dividends may be paid only after other shareholders receive theirs, or voting or redemption rights may be postponed. For investors, that timing difference matters because deferred shares typically offer lower near-term income and different risk, affecting expected returns, priority in payouts, and the share’s market value; think of them like a delayed paycheck compared with a regular salary.

GRAT financial

"These shares are held in a GRAT"

Imputed reinvestment of dividends financial

"Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MET (MetLife Inc) disclose for Daniel S. Glaser?

MetLife disclosed that director Daniel S. Glaser acquired 10 shares of common stock on September 8, 2026 via imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors.

At what value were the new MET shares credited to Daniel S. Glaser?

The 10 MetLife (MET) shares were credited at a reference value of $95.50 per share, as part of the dividend reinvestment on deferred shares under the company’s Deferred Compensation Plan for Non-Management Directors.

How many MET shares does Daniel S. Glaser hold directly after this transaction?

After the September 8, 2026 transaction, Daniel S. Glaser holds 2,705 shares of MetLife (MET) common stock in direct ownership, according to the reported post-transaction holdings.

Does Daniel S. Glaser have any indirect holdings of MET shares?

Yes. In addition to his direct holdings, Daniel S. Glaser has 198 shares of MetLife (MET) common stock held indirectly by a GRAT, as disclosed in the filing footnotes.

Was the MET insider transaction made under a Rule 10b5-1 trading plan?

No. The filing indicates the Rule 10b5-1 checkbox is not affirmed for this Form 4, and the footnotes describe the acquisition as an imputed reinvestment of dividends on deferred shares rather than under a trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Glaser Daniel S

(Last) (First) (Middle)

METLIFE, INC.

200 PARK AVENUE

(Street)

NEW YORK NEW YORK 10166

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
METLIFE INC [ MET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/08/2026		A(1)		10	A	$95.5	2,705	D
Common Stock								198(2)	I	By GRAT

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.

2. These shares are held in a GRAT.

Remarks:

	/s/ Morgan Keehner-Jones Mayes, Attorney-in-fact	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)